Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.
Explore this paper's citation graph
Summary
The fact that the decrease in IHD deaths was directly related to the degree of serum triglyceride lowering indicates that it was the drug effect on serum lipids that was responsible for the beneficial effect of the treatment.
- Type
- article
- Published
- 2009-04-24
- Cited by
- 687
- References
- 31
- OpenAlex
- https://openalex.org/W2070999659
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:21324746
Keywords
Medicine, Clofibrate, Triglyceride, Internal medicine, Gastroenterology
References
- Hypertriglyceridemia: lipoprotein receptors and atherosclerosis.
- Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women.
- Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Results from a 10-year follow-up of Uppsala primary preventive study.
- Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men.
- The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study.
- Accumulation of cholesteryl esters and triglycerides in cultured macrophages incubated with plasma very low density lipoproteins from rats fed on casein or soybean protein diets containing moderate levels of cholesterol.
- Lipoproteins and atherosclerosis. A look back and a look ahead.
- Quantitative and qualitative serum lipoprotein analysis. Part 1. Studies in healthy men and women.
- Ischaemic Heart Disease and Associated Risk Factors in 40 Year Old Men in Edinburgh and Stockholm
- A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate.
- Effect of combined clofibrate--nicotinic acid treatment in ischemic heart disease.
- Triglycerides--main lipid risk factor for cardiovascular disease in women?
- The origin of the innocent "vibratory" murmur studied with intracardiac phonocardiography.
- Serum lipids in normal men.
- Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.
- Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study.
- Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid.
- High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.
- Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
- Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
Cited by
- Prevention and regression of atherosclerosis with drug therapy
- Fish oil and plasma fibrinogen.
- Cholesterol lowering does have a role in secondary prevention.
- The effects of lowering serum cholesterol on coronary heart disease risk.
- Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)
- Intermediate-density lipoproteins, diabetes and coronary artery disease.
- Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
- High-density lipoprotein cholesterol therapies: the next frontier in lipid management.
- Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
- Revisiting niacin: reviewing the evidence.
- High-density lipoproteins: a consensus statement from the National Lipid Association.
- High-density lipoprotein and coronary heart disease: current and future therapies.
- Management of hypertriglyceridemic patients. A. Treatment classifications and goals.
- Pharmacotherapy of Dyslipidemia
- Dietary and pharmacologic management of cholesterol.
- Drug benefit plans for elderly under managed care and utilization of lipid lowering agents
- Addressing Lipid Treatment Targets Beyond Cholesterol: A Role for Prescription Omega-3 Fatty Acid Therapy
- Optimising Outcomes in Secondary Prevention of Coronary Heart Disease
- Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias.
- An Investigation of the Health Benefits of Honey as a Replacement For Sugar In the Diet
Related papers
- A comparison of clofibrate and its derivative methyl clofenapate.
- Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
- The Mechanism of Action of Clofibrate and Tetranicotinoylfructose (Bradilan) on the Kinetics of Plasma Free Fatty Acid and Triglyceride Transport in Type IV und Type V Hypertriglyceridaemia
- Inhibition of hepatic triglyceride formation by clofibrate.
- Hypocholesterolaemia in the rat after p-chlorophenoxyisobutyric acid (CPIB) administration as a synthetic triglyceride, 1,3-dipalmitoyl 2(p-chlorophenoxyisobutyroyl)-rac-glycerol.
- EFFECT OF CLOFIBRATE ON SERUM TRIGLYCERIDE AND CHOLESTEROL AFTER INTRAVENOUS LIPID IN VERY LOW BIRTH WEIGHT NEONATES
- The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post heparin plasma in male patients with hyperlipoproteinemia.